Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 193
Selected: 0
NCT IDTitle
NCT00030420Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00459121Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery
NCT00244933Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer
NCT01728259First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
NCT00288028Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant
NCT00004022Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma
NCT01504711Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy
NCT01208662Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
NCT07227831A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
NCT00003220Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer
NCT00618826A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer
NCT03683420Music in Reducing Distress in Participants with Cancer During Chemotherapy Treatment
NCT02521090EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma
NCT02037256Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
NCT03183050MEND 2: Making Treatment Decisions Using Genomic Testing
NCT00020722Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer
NCT00258232Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer
NCT01643603Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
NCT00005027Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer
NCT00482846Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
NCT00078923Soy Isoflavones in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage I or Stage II Adenocarcinoma of the Prostate
NCT07735819Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma
NCT00768118A Nutritional Supplement Capsule Containing Curcumin, Green Tea Extract, Polygonum Cuspidatum Extract, and Soybean Extract in Healthy Participants
NCT00248560Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
NCT02145078Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer
NCT04237584A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients
NCT00003171Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome
NCT00244946Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma
NCT00503841Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer
NCT00258466Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
NCT01116232Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
NCT01888198Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment
NCT00303901Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery
NCT04266522Medical Physics Direct Patient Care for the Improvement of Patient Understanding of Care
NCT00258245Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
NCT01147016Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
NCT01415089Tailored Web-Based Intervention for Cancer Patients and Family Caregivers
NCT00016185Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors
NCT03657511Tobacco Cessation Intervention
NCT02372877Evaluation of the AMICUS RBCx System in Sickle Cell Patients
NCT03875053Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Cancer
NCT01813370A Registry for Patients Treated on the Clinical Trial TAX 3503
NCT00499694Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel
NCT00003936Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease
NCT02269267The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
NCT03091257A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT03033914A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
NCT03750981C.A.P.A.B.L.E. (CrossFit® and Physical Activity: A Better Life Experience)
NCT00942422Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma
NCT02472275PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer